Curaleaf (OTCMKTS:CURLF – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.
Profitability
This table compares Curaleaf and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Curaleaf | -0.76% | 0.43% | 0.13% |
| Profound Medical | -137.51% | -59.57% | -47.87% |
Analyst Ratings
This is a breakdown of current recommendations for Curaleaf and Profound Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curaleaf | 0 | 1 | 2 | 1 | 3.00 |
| Profound Medical | 1 | 0 | 1 | 1 | 2.67 |
Curaleaf presently has a consensus target price of $6.00, indicating a potential downside of 23.57%. Profound Medical has a consensus target price of $11.50, indicating a potential upside of 54.99%. Given Profound Medical’s higher probable upside, analysts plainly believe Profound Medical is more favorable than Curaleaf.
Insider & Institutional Ownership
0.0% of Curaleaf shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Curaleaf has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.
Valuation & Earnings
This table compares Curaleaf and Profound Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curaleaf | $1.27 billion | 1.45 | -$231.07 million | ($0.04) | -196.25 |
| Profound Medical | $16.10 million | 16.88 | -$42.57 million | ($0.93) | -7.98 |
Profound Medical has lower revenue, but higher earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Curaleaf beats Profound Medical on 8 of the 14 factors compared between the two stocks.
About Curaleaf
Curaleaf Holdings, Inc. is a cannabis company that cultivates, processes and sells cannabis products for medical and adult-use markets. Its products include cannabis flower, pre-rolls, concentrates, vapes, edibles, tinctures and topical products, sold under brands including Curaleaf, Select and Grassroots. The company operates across multiple U.S. markets through cultivation and processing facilities, wholesale operations and retail dispensaries. Through Curaleaf International, it also serves medical cannabis markets in Europe and other international markets.
About Profound Medical
Profound Medical Corp. is a Canadian medical-device company that develops MRI-guided therapies using focused ultrasound. Its systems combine magnetic resonance imaging with ultrasound energy to help clinicians target and treat tissue without conventional open surgery. The company’s TULSA-PRO system is designed to ablate prostate tissue. It also offers Sonalleve, an MRI-guided focused-ultrasound platform developed for applications including the treatment of uterine fibroids and the palliation of pain from bone metastases.
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
